Navigation Links
Lemelson Capital Comments on Large Institutional Selling in Shares of Ligand Pharmaceuticals Amidst Company's Insolvency and Mounting Going Concern Risk
Date:8/25/2014

MARLBOROUGH, Mass., Aug. 25, 2014 /PRNewswire/ -- Lemelson Capital Management, a private investment management firm, today released additional research and comments on Ligand Pharmaceuticals (NASDAQ: LGND) amidst the company's unusual and complex debt arrangement under which the firm has assumed $245 million in debt principally so that large institutional shareholders can offload shares of the troubled company in private transactions at undisclosed prices.  In what is likely the first in a series of large institutional share sales of Ligand, the company's largest shareholder, BVF, Inc., revealed to the U.S. Securities and Exchange Commission (SEC) this week that it has sold 484,524 shares of the company's stock.

"Ligand Pharmaceuticals is an insolvent company facing severe competitive threats to its key royalty programs that has now absorbed an extraordinary amount of costly debt apparently to allow their largest shareholders to liquidate their holdings as 'going concern risk' at the company grows," Lemelson Capital Management Chief Investment Officer Emmanuel Lemelson said today.  "This transaction reaffirms our prior research thesis that Ligand has justifiably lost favor with its largest investors and has dramatically increased the likelihood of the company eventually being forced to seek protection from creditors," he added.

The report on Ligand can be found here.

Lemelson Capital's previous research reports (PDF versions) on Ligand can be found herehere and here.

Lemelson Capital Management first announced its short position in Ligand Pharmaceuticals on June 16, 2014.  The stock has undergone a significant 26 percent correction since.  "We reiterate our position that the intrinsic value for Ligand is zero and see these large institutional sales as an indication that our concerns are increasingly broadly held," Lemelson said.

Disclosure:  Lemelson Capital is currently short shares of LGND for its clients.

About Lemelson Capital Management:

Lemelson Capital Management, LLC is a private investment management firm focused on deep value and special situation investments.  The firm's flagship fund, The Amvona Fund, has been named repeatedly one of the world's top performing hedge funds.  For more information, see: http://www.lemelsoncapital.com.

Contact:
+Emmanuel Lemelson
Chief Investment Officer
Lemelson Capital Management, LLC
(508) 630-2281

 


'/>"/>
SOURCE Lemelson Capital Management, LLC
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Lemelson Capital Management Further Increases Short Position in Ligand Pharmaceuticals (NASDAQ: LGND), Updates LGND Research Report with New Material Information
2. Cardiva Medical, Inc. Announces Completion of the first two tranches of Series 3 Private Equity Financing and the Closing of a Senior Secured Debt Facility with GE Capital
3. Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market
4. BiOptix Announces Additional $1.4M in Funding to Aid in Commercialization and Working Capital Needs
5. Northsight Capital, Inc. Names Wall Street Veteran John Bluher, Former EVP And General Counsel Of Knight Trading Group, Chairman And CEO.
6. Creekridge Capital Signs Several New Vendor Partners
7. Phosphagenics A$19.3 million Capital Raising
8. Echo Therapeutics to Present at the Noble Financial Capital Markets Tenth Annual Equity Conference
9. Equipment Dealers Applaud Direct Capitals Finance Solutions
10. Pre-Market Update: MGT Capital Investments, National American University Holdings and Actinium Pharmaceuticals
11. Nutrastar International Inc. Announces That Acclaimed Value Investor, Accretive Capital Partners, Significantly Increased Its Ownership of the Company through Private Transactions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)...  ivWatch LLC, a medical device company focused on ... is pleased to announce it was the Bronze Winner ... and Equipment at the 2017 Medical Design Excellence Awards ... The award was presented by Medical Device and Diagnostics ... New York during MD&M East, ...
(Date:6/11/2017)... and Company (NYSE: LLY ) announced today ... an investigational treatment for the prevention of episodic and ... endpoints for galcanezumab compared to placebo at both studied ... REGAIN) will be presented today at the American Headache ... . "The detailed Phase 3 ...
(Date:6/8/2017)... Responding to Heath Ledger,s father,s recent call for ... Chris Cornell in May, the mental health watchdog group, ... psychiatric drug side effects search engine ... risks. The father of the late actor ... has called for tighter rules on prescription drugs. Speaking at ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... ... the launch of Care Management Alerts and Dashboards, an innovative new service enabling ... Island. , RIQI’s Care Management Alerts and Dashboards provide near real-time data about ...
(Date:6/23/2017)... Beach, CA (PRWEB) , ... June 23, 2017 , ... ... has earned its ninth consecutive four-star rating from premier online charity evaluator, Charity Navigator, ... in the top 1% of all charities reviewed by Charity Navigator and earns ANRF ...
(Date:6/23/2017)... ... June 24, 2017 , ... Studies show evidence that carotenoids ... risk of visual loss in these patients. , But how often do ophthalmologists and ... cessation to patients at risk of or with early symptoms of AMD? A ...
(Date:6/23/2017)... Newburgh, NY (PRWEB) , ... June 23, 2017 ... ... board certified plastic surgeon practicing in Newburgh, New York, has recently begun offering ... look. Committed to offering the best cutting-edge procedures and reducing downtime, Dr. Rubinstein ...
(Date:6/23/2017)... , ... June 23, 2017 , ... Everybody has their ... while others prefer to read it, and some people don't like it at all. ... Here's what they found: , Erotic literature can give readers a taste of their ...
Breaking Medicine News(10 mins):